OptiNose

OptiNose — Corporate Update (June 2022)

16 slides from OptiNose's corporate update, Jun 13, 2022

  1. Slide 1: ReOpen2 Clinical Trial Top-Line Results

    ReOpen2 Clinical Trial Top-Line Results J u n e 1 3 , 2 0 2 2

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this

  3. Slide 3: Chronic Sinusitis Overview

    optinose_ ——— Chronic Sinusitis Overview

  4. Slide 4: What is Chronic Sinusitis (CS)

    4 What is Chronic Sinusitis (CS) CS is an inflammatory disease of the paranasal sinuses that is defined by the presence of at least two out of four cardinal symptoms (i.e., facial pain/pressure, hyposmia/anosmia, nasal drainage, and nasal obstruction) for at least 12 consecutive weeks, in addition t

  5. Slide 5: ReOpen2: A Confirmatory Trial of XHANCE for Treatment of Chronic Sinusitis

    ReOpen2 A Confirmatory Trial of XHANCE for Treatment of Chronic Sinusitis: Design and Top-Line Results

  6. Slide 6: ReOpen2 Trial Design Summary

    6 EDS Placebo 372 μg Week 24 Double Blinded Phase En d of St ud y ReOpen2 Trial Design Summary Randomized, double-blind, EDS-vehicle (placebo) controlled, parallel-group, multicenter study evaluating efficacy and safety of XHANCE 1 or 2 sprays (186 μg or 372 μg) twice daily in subjects with CS who d

  7. Slide 7: ReOpen2: Disposition and Baseline Characteristics

    7 ReOpen2: Disposition and Baseline Characteristics EDS-vehicle (Placebo) XHANCE 186 mcg XHANCE 372 mcg Subjects Randomized 75 74 74 Subjects Treated 75 73 74 Subjects Who Completed Study 69 70 71 Subjects Discontinuing Early* 6 (8%) 3 (4.1%) 3 (4.1%) Full Analysis Set 75 72 73 Mean Baseline CSS Sco

  8. Slide 8: ReOpen2: Combined Symptom Score (Co-Primary Endpoint)

    8 ReOpen2: Combined Symptom Score (Co-Primary Endpoint) 1 -0.81 -1.54* -1.74‡ -2.0 -1.8 -1.6 -1.4 -1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0 CS S Po in t R ed uc tio n LS Mean Change in CSS from Baseline to Week 4 EDS-placebo BID OPN-375 186 μg BID OPN-375 372 μg BID BID, twice daily; CSNS, composite symptom

  9. Slide 9: ReOpen2: Average of Percentages of Opacified Volume

    9 ReOpen2: Average of Percentages of Opacified Volume (Ethmoid and Maxillary) Objective Evidence of Effect in Sinus Cavities by CT Scan; Co-Primary Endpoint 1.19 -7.00‡ -5.14♰ -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 Pe rc en t R ed uc tio n LS Mean Change in APOV of the Ethmoid and Maxillary Sinuses from Base

  10. Slide 10: AEs Occurring in ≥3% of Patients and More Common Than Placebo

    10 AEs Occurring in ≥3% of Patients and More Common Than Placebo Adverse Event (AE) EDS-placebo BID (N =75) n (%) XHANCE 186 mcg BID (N =73) n (%) XHANCE 372 mcg BID (N =74) n (%) COVID-19 2 (2.7) 3 (4.1) 7 (9.5) Epistaxis 0 (0.0) 4 (5.5) 7 (9.5) Headache 6 (8.0) 2 (2.7) 7 (9.5) Depression 1 (1.3) 0

  11. Slide 11: Anticipated Next Steps

    11 Anticipated Next Steps  Complete analysis of ReOpen2  Complete pre-specified pooled analyses of ReOpen1/2 data – Notably, reduction of disease exacerbations is an important endpoint pre-specified to be evaluated in pooled data  Meeting with FDA prior to data submission  Development of sNDA un

  12. Slide 12: Market Opportunity

    optinose_ —— Market Opportunity

  13. Slide 13: XHANCE as First FDA-approved Drug Treatment for Chronic Sinusitis Creates New Growth Opportunities

    13 Successful Development of XHANCE as the First FDA-approved Drug Treatment for Chronic Sinusitis Creates Multiple New Opportunities for Growth Up to ~1 Million patients with nasal polyps (NP) are treated by specialty physicians in our current sales deployment $1B TAM $3B TAM Up to ~10 Million pati

  14. Slide 14: Chronic Sinusitis Treatment Would Increase Opportunity and Address Prescribing Barriers

    14 Successful Development of XHANCE as a Treatment for Chronic Sinusitis Would Increase Opportunity and Address Certain Barriers to Broader Prescribing that Exist Today Insurance  Today, ~80% of commercial lives are in plans that cover XHANCE, but ~half require physicians to attest that they are pr

  15. Slide 15: Closing Remarks and Q&A

    optinose_ ——— Closing Remarks and Q&A

  16. Slide 16: ReOpen2 Clinical Trial Top-Line Results

    ReOpen2 Clinical Trial Top-Line Results J u n e 1 3 , 2 0 2 2

OptiNose — Corporate Update (June 2022) on 6ix